Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IQV logo IQV
Upturn stock ratingUpturn stock rating
IQV logo

IQVIA Holdings Inc (IQV)

Upturn stock ratingUpturn stock rating
$188.73
Last Close (24-hour delay)
Profit since last BUY21.97%
upturn advisory
Consider higher Upturn Star rating
BUY since 49 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: IQV (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

23 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $215.05

1 Year Target Price $215.05

Analysts Price Target For last 52 week
$215.05 Target price
52w Low $134.65
Current$188.73
52w High $252.69

Analysis of Past Performance

Type Stock
Historic Profit 26.04%
Avg. Invested days 43
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 32.44B USD
Price to earnings Ratio 27.61
1Y Target Price 215.05
Price to earnings Ratio 27.61
1Y Target Price 215.05
Volume (30-day avg) 23
Beta 1.3
52 Weeks Range 134.65 - 252.69
Updated Date 08/29/2025
52 Weeks Range 134.65 - 252.69
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 6.91

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 7.88%
Operating Margin (TTM) 13.39%

Management Effectiveness

Return on Assets (TTM) 5.16%
Return on Equity (TTM) 19.79%

Valuation

Trailing PE 27.61
Forward PE 16
Enterprise Value 45596100000
Price to Sales(TTM) 2.07
Enterprise Value 45596100000
Price to Sales(TTM) 2.07
Enterprise Value to Revenue 2.9
Enterprise Value to EBITDA 13.61
Shares Outstanding 170000000
Shares Floating 161462600
Shares Outstanding 170000000
Shares Floating 161462600
Percent Insiders 1.05
Percent Institutions 102.09

ai summary icon Upturn AI SWOT

IQVIA Holdings Inc

stock logo

Company Overview

overview logo History and Background

IQVIA Holdings Inc. was formed in 2017 through the merger of IMS Health and Quintiles. IMS Health, founded in 1954, focused on healthcare data and analytics. Quintiles, established in 1982, was a leading contract research organization (CRO). The merger created a comprehensive provider of biopharmaceutical development and commercial outsourcing services.

business area logo Core Business Areas

  • Technology & Analytics Solutions (TAS): Provides data, analytics, and technology solutions to healthcare clients, including pharmaceutical companies, healthcare providers, and payers. This includes real-world data, market research, and software platforms.
  • Research & Development Solutions (RDS): Offers contract research organization (CRO) services, supporting biopharmaceutical companies in clinical trials and drug development. This includes clinical trial management, data management, and regulatory consulting.

leadership logo Leadership and Structure

Ari Bousbib is the Chairman and CEO. The organizational structure includes various business units and functional departments reporting to the CEO, with a board of directors providing oversight.

Top Products and Market Share

overview logo Key Offerings

  • IQVIA CORE: A suite of data, analytics, and technology solutions that provide insights into healthcare trends, patient behavior, and market dynamics. Estimated market share within healthcare data and analytics is approximately 25%. Key competitors include Veeva Systems (VEEV), Oracle Cerner (ORCL), and Accenture (ACN).
  • Clinical Trial Management Services: Provides comprehensive clinical trial management services, including protocol development, site selection, patient recruitment, and data management. Holds a significant share of the CRO market, competing with Labcorp (LH), Thermo Fisher Scientific (TMO), and Charles River Laboratories (CRL).

Market Dynamics

industry overview logo Industry Overview

The healthcare industry is undergoing significant transformation, driven by factors such as increasing healthcare costs, aging populations, and technological advancements. There is a growing demand for data-driven insights and outsourcing solutions.

Positioning

IQVIA is a leading player in the healthcare intelligence and clinical research space. Its competitive advantages include its comprehensive data assets, global reach, and integrated service offerings.

Total Addressable Market (TAM)

The TAM for healthcare technology and CRO services is estimated to be over $200 billion. IQVIA is well-positioned to capture a significant share of this market due to its broad portfolio and established relationships.

Upturn SWOT Analysis

Strengths

  • Extensive data assets
  • Global reach
  • Integrated service offerings
  • Strong brand reputation
  • Experienced management team

Weaknesses

  • High debt levels
  • Integration risks from acquisitions
  • Dependence on pharmaceutical industry
  • Potential for data privacy breaches
  • Complex organizational structure

Opportunities

  • Growing demand for healthcare data and analytics
  • Expanding CRO market
  • Increasing adoption of technology in healthcare
  • Opportunities in emerging markets
  • Potential for strategic partnerships

Threats

  • Intense competition
  • Regulatory changes
  • Economic downturn
  • Data privacy and security concerns
  • Technological disruption

Competitors and Market Share

competitor logo Key Competitors

  • VEEV
  • LH
  • TMO
  • ACN
  • ORCL

Competitive Landscape

IQVIA holds a strong position due to its comprehensive data assets and integrated service offerings, but faces competition from specialized players like Veeva in software and larger CROs like Labcorp.

Major Acquisitions

Deep Current

  • Year: 2021
  • Acquisition Price (USD millions): 0
  • Strategic Rationale: Enhance patient data and real world insights into US healthcare

ADVANZ Pharma's Global Generics Business

  • Year: 2020
  • Acquisition Price (USD millions): 0
  • Strategic Rationale: Gain access to broader product portfolio to provide services.

Growth Trajectory and Initiatives

Historical Growth: IQVIA has experienced steady growth in recent years, driven by organic growth and acquisitions.

Future Projections: Analysts project continued growth for IQVIA, driven by demand for its data and analytics solutions and CRO services.

Recent Initiatives: IQVIA has been focused on expanding its data assets, investing in technology, and entering new markets.

Summary

IQVIA is a strong company with a leading position in the healthcare intelligence and clinical research space. Its comprehensive data assets and integrated service offerings provide a competitive advantage. However, high debt levels and reliance on the pharmaceutical industry pose potential risks. Expansion in emerging markets and strategic partnerships offer opportunities for future growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings (10-K, 10-Q)
  • Market Research Reports
  • Analyst Reports
  • Company Website

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About IQVIA Holdings Inc

Exchange NYSE
Headquaters Durham, NC, United States
IPO Launch date 2013-05-09
CEO & Chairman Mr. Ari Bousbib
Sector Healthcare
Industry Diagnostics & Research
Full time employees 90000
Full time employees 90000

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. It has a strategic collaboration with Sarah Cannon Research Institute to enhance clinical trial processes. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.